35 results about "Plga peg plga" patented technology

The invention discloses a novel PLGA-PEG-PLGA multipolymer microbubble ultrasound contrast agent and preparation method thereof. The microbubble ultrasound contrast agent is provided with an outer housing prepared from the polymer material PLGA-PEG-PLGA, the components of the inner core of gas include perfluoropropane, decafluorobutane or sulphur hexafluoride, and the like, and the molecular weight of the PLGA-PEG-PLGA multipolymer ranges from 2000 to 20000 dal. The preparation of the agent adopts the double emulsion method, and after being frozen and dried, gas molecules are led into microbubbles. The multipolymer microbubble contrast agent has favorable backscattering performance, shows the enhanced effect of ultrasonic contrast during in vivo and in vitro experiments, is safe and nontoxic, and meets the requirement of the ultrasound contrast agent.

A sustained-release gel injection comprises sustained-release microspheres containing taxanes drug, amphiphilic block copolymer, solvent and release regulator, wherein the mixture of the amphiphilic block copolymer and the solvent has a temperature sensitive gelatinization characteristic, and can automatically become non-flowing degradable water insoluble gel, which can locally and slowly release drug at tumor foci for several weeks to several months, after injection into body. The preparation can be injected into or around a tumor for treating solid tumors at different stages. The preparation has the effects of controlling residual tumor cells relapsed after operation and tumors that can not be excised via operation, controlling complications at late stage of tumors, and enhancing treatment effect of chemotherapy and radiotherapy (particularly radioactive particles). The taxanes are selected from docetaxel, taxol, epitaxol, hydroxyl taxol and deacetyltaxol; the amphiphilic block copolymer is PLGA-PEG-PLGA copolymer, wherein the PEG has molecular weight of 1200-1600, accounting for 20 wt% of the amphiphilic block copolymer; and in the glycolide-lactide copolymer, the mol ratio of glycolide and lactide is 6:1.

The invention discloses a polyester carbonic ester anhydride 3D printing bio-ink, and a 3D printing method. The polyester carbonic ester anhydride 3D printing bio-ink is composed of a gel ink and a support ink; the gel ink is composed of a hydrogel and biological cells; the hydrogel contains a PLGA-PEG-PLGA triblock copolymer with temperature responsiveness; the support ink is a polyester carbonic ester anhydride copolymer (P(LLA-TMC-SA)copolymer) with surface degradation characteristics. The 3D printing bio-ink possesses thermosensitivity and surface degradable performance, and multicomponent gradient printing and coaxial printing are adopted based on requirements of 3D biologically printed scaffold in vivo degradation structure controllable maintenance so as to obtain models which contain biological cells and are supported by scaffolds with surface controllable degradability, nutrient and metabolism channels with porous structures are obtained, and it is beneficial for obtaining of larger and thicker tissue structures via 3D printing.

The invention relates to a temperature-sensitive hydrogel containing exendin-4, comprising exendin-4 as an effective ingredient and an amphiphilic copolymer as a medicine slow release carrier, wherein, the amphiphilic copolymer comprises polyester and polyethylene glycol, preferred PLGA-PEG-PLGA. The temperature-sensitive hydrogel is a liquid at room temperature, and is a solid water insoluble gel at the temperature of 37 DEG C, can be used for treating diabetes, and has good drug release property, environmental protection, little irritation, convenient application, and obvious effect. Compared with preparations with a large dose of exendin-4, the hydrogel disclosed herein has the advantages of in vivo formation of gel, easy operation, and continuous release property, and improves bioavailability, reduces administration times, and enhances patient compliance.

The invention discloses a perfluorooctylbromide coated block polymer ultrasound microbubble contrast agent and a preparation method thereof. The perfluorooctylbromide coated block polymer ultrasound microbubble contrast agent refers to a perfluorooctylbromide coated mPEG-PLLA, PLGA-PEG-PLGA or mPEG-PCL block polymer ultrasound microbubble contrast agent. A preparation method of the agent comprises the steps of preparing an mPEG-PLLA, PLGA-PEG-PLGA or mPEG-PCL block polymer solution, adding perfluorooctylbromide perfluoropentane, perfluorohexane or perfluoropropane to the solution, and then preparing the ultrasound microbubble contrast agent by an electric internal cutting homogenizing, ultrasonic emulsifying or mechanical oscillating method. The perfluorooctylbromide coated block polymer ultrasound microbubble contrast agent provided by the invention is applied to preparation of an ultrasonic imaging diagnosis contrast agent. The high polymer material used by the perfluorooctylbromide coated block polymer ultrasound microbubble contrast agent is safe and nontoxic, and is obviously cheaper than synthetic phospholipids; the microbubble preparation process is simple and convenient; the novel perfluorooctylbromide coated block polymer ultrasound microbubble contrast agent has good potential prospect in clinical application.

The invention discloses temperature-sensitive gel containing ropivacaine and used for long-acting injection and a preparation method of the temperature-sensitive gel. The gel comprises a main drug ropivacaine, ropivacaine hydrochloride or ropivacaine mesylate, a PLGA (poly (lactic-co-glycolic acid)) -PEG (polyethylene glycol)-PLGA copolymer as well as water, normal saline or pH regulation solution for injection, wherein the mole ratio of lactide to glycolide is (2-3): 1, and the PEG molecular weight of the PLGA-PEG-PLGA copolymer is 1,000. The preparation method comprises the following steps: the copolymer is sufficiently swelled in a solvent firstly, then the main drug is added, and sterilization is performed through a filter membrane. The temperature-sensitive gel facilitates drug delivery and can gel rapidly at human body temperature so as to play a slow release role, smaller than or equal to 35%-45% of the drug is released in vitro after 12 h, larger than or equal to 65%-75% of the drug is released after 48 h, larger than or equal to 80% of the drug is released after 72 h, and the design requirement for postoperative continuous analgesia for 48 h through single injection of a local anesthesia drug is met. Pharmacodynamics study shows that a temperature-sensitive gel group containing ropivacaine can prolong the efficacy maintaining time remarkably and continuously play 48 h analgesic effect.

The invention relates to processing of macromolecular materials, and in particular relates to a poly lactic acid-glycolic acid (PLGA)-polyethylene glycol (PEG)-PLGA triblock copolymer and a preparation method thereof. According to the PLGA-PEG-PLGA triblock copolymer provided by the invention, the number-average molecular weight of the PLGA is more than 2,000; and the number-average molecular weight of the PEG is 2 to 5 times that of the PLGA. Compared with the traditional PLGA-PEG-PLGA which is matched and polymerized by PLGA and PEG with Mn less than 2,000, the aqueous solution of the PLGA-PEG-PLGA triblock copolymer provided by the invention has a wider solution-gel conversion area.

The invention discloses a medicine-loaded nanoparticle vector and temperature-sensitive gel compounding system and a preparation method thereof. The preparation method includes the following steps that nanoparticle vectors are prepared; medicine molecules are connected with amino groups or hydroxyl groups at the ends of polyamidoamine dendrimers in a covalent bonding mode, and a medicine-loaded polyamidoamine dendrimer polymer is prepared; temperature-sensitive gel is prepared, the temperature-sensitive gel is a PLGA-PEG-PLGA copolymer, PLGA is a lactide-glycolide copolymer, and PEG is a polyethylene glycol copolymer; a copolymer solution is prepared by putting the PLGA-PEG-PLGA copolymer into a solvent; and under the condition of stirring, the medicine-loaded polyamidoamine dendrimer polymer is added into the copolymer solution, stirring is continued, and the medicine molecule-loaded nanoparticle vector and temperature-sensitive gel compounding system is obtained. The medicine-loaded nanoparticle vector and temperature-sensitive gel compounding system has a dual slow release function, and can stimulate synovial membrane mesenchymal cells to develop into cartilage cells, relieve the inflammation of a cartilage injured part, and promote the injury repair process of articular cartilages.

An anticancer sustained-release gel injection sustained-release microspheres containing platinum-based compound, amphiphilic block copolymer, solvent and release regulator, the mixture of amphiphilic block copolymer and solvent has a temperature sensitive gelatinization characteristic, and can automatically become non-flowing degradable water insoluble gel, which can locally and slowly release drug at tumor foci for several weeks to several months, after injection into body. The adjuvant in the sustained-release microspheres is poly(lactic acid)-glycollic acid copolymer; and the amphiphilic block copolymer is PLGA-PEG-PLGA copolymer. The preparation can be injected into artery, inside a tumor or around a tumor with remarkably reduced systemic toxicity of drug, and can be used for solid tumors at different stages. The platinum-based compound is selected from nedaplatin, carboplatin, cisplatin, enloplatin, ormaplatin, sulfato-1,2-diaminocyclohezane-platinum (SHP), picoplatin, cyclopentylamine platium, zeniplatin, spiroplatin, lobaplatin, iproplatin, oxaliplatin, cycloplatin, and dexormaplatin. The preparation can be used with radioactive particles and can enhance chemotherapy effect.

The invention relates to a 2-methoxy estradiol injectable hydrogel implant which can effectively solve the problems of maintaining the effective concentration of the target part of 2-methoxy estradiol and enhancing the treatment effect. The invention has the technical scheme that a temperature sensitive type PLGA-PEG-PLGA segmented copolymer having temperature sensitive hydrogel properties is adopted to be mixed with water to prepare dissolution swelling solution; the solution is mixed with the 2-methoxy estradiol to prepare an injection; the temperature sensitive type PLGA-PEG-PLGA segmented copolymer is uniformly mixed with the water to be kept stewing at 0 to 25 DEG C; the temperature sensitive type PLGA-PEG-PLGA segmented copolymer is fully dissolved and swelled into the solution; and the 2-methoxy estradiol is added to be uniformly mixed with solution at 0 to 25 DEG C on the use day or one day before use. The invention has scientific formula, easy production, low cost and good injection effect, can effectively maintain the effective concentration of the target part of the 2-methoxy estradiol and enhance the treatment effect is enhanced and is the innovation on the path of cancer treatment drug forms and drug administration.

The invention relates to the fields of biological functional materials and nanotechnologies and particularly relates to a novel amphiphilic polymer nano medicine carrying micelle which is proper in particle size distribution range, stable in encapsulation rate and medicine carrying rate, high in biological safety and capable of increasing bioavailability of ursolic acid and a structural modifier thereof. The technical scheme of the invention provides a medicine carrying micelle capable of increasing bioavailability of ursolic acid and a structural modifier thereof. The medicine carrying micelle is characterized in that the preparation method comprises the following steps of 1, synthesizing PLGA-PEG-PLGA (poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid)) by using a ring opening polymerization method; 2, simultaneously dissolving an insoluble drug and a triblock copolymer into an organic solvent to prepare an oil phase; 3, dropwise adding the oil phase into a water phase stirred at a high speed; 4, stirring until the oil phase is completely volatilized, and filtering a membrane in the solution to obtain a medicine carrying nanoparticle contained ultrapure water solution; freezing and drying to obtain the medicine carrying micelles.

The invention discloses an application of a PLGA-PEG-PLGA (poly(lactic acid-glycolic acid)-polyethylene glycol-poly(lactic acid-glycolic acid)) triblock copolymer in medicine loading and a slow-release medicine, and a preparation method of the PLGA-PEG-PLGA triblock copolymer. The PLGA-PEG-PLGA triblock copolymer is especially suitable for treatment of periodontitis. A water solution of the PLGA-PEG-PLGA triblock copolymer is subjected to solution-gel phase transformation along with the temperature increment; the phase transformation temperature is 35-39 DEG C; the medicine-loaded water solution of the PLGA-PEG-PLGA triblock copolymer becomes medicine-loaded gel after being injected into a human body; and the medicine-loaded gel is capable of releasing the medicine within 6-8 days. The PLGA-PEG-PLGA triblock copolymer water solution is suitable for application as a medicine carrier and a slow-release medicine.

The invention discloses a PLGA (poly(lactic-co-glycolic acid))-PEG (poly(ethylene glycol))-PLGA inlaid mineralized collagen coating and its preparation method. The method of the invention conducts electrochemical deposition, adjusts deposition parameters, constructs a mineralized collagen coating with a porous structure on a metal implant surface, and inlays a temperature sensitive polymer PLGA-PEG-PLGA into the structure, so that the coating becomes an excellent drug slow release system and can be used for controlled release of biotic factors, antibiotics and other drugs in vivo. PLGA-PEG-PLGA can make sol-gel conversion with temperature variation. On account of the characteristic, biotic factors and antibiotics, etc. are loaded under a sol state of PLGA-PEG-PLGA, under the gel state of which the drugs can be released, thus optimizing the slow release behavior of the coating. The coating prepared by the method of the invention can make use of mineralized collagen to transmit biological signals and the temperature sensitive polymer to control drug release effectively, so that the coating can has high biological responsiveness as well as a good drug slow release function simultaneously, thus boasting wide application prospects in hard bone tissue repair field.

The present invention relates to a preparation method of temperature-sensitive triblock polymer (PLGA-PEG-PLGA), which pertains to the field of high polymer medical materials and medical technology. The copolymer makes use of an open-loop copolymerization method, takes the polyethylene glycol (PEG), D, L-lactide, glycolic as the raw materials and is prepared by the polymerization with the involvement of an initiator. The gel-sol phase transition temperature (40 DEG C to 44 DEG C) can meet the requirements on the clinical application of local temperature-oriented drug target, which can not only be higher than the human physiological temperature, but also be in the affordable scope of the human body at the same time. The polymer is the pharmaceutical material, which can be mixed with the drug to prepare the microcapsules, micro-particles, nanoparticles and other preparations, so the present invention has potential application in a local temperature-oriented targeting delivery system.

The invention relates to the technical field of medicinal preparations, and in particular relates to an in-vivo in-situ drug-loading hydrogel carrier as well as a preparation method and applications of the in-vivo in-situ drug-loading hydrogel carrier. For the in-vivo in-situ drug-loading hydrogel carrier PLGA-PEG-PLGA, the hydrogel carrier is formed by polymerizing lactide LA, polyethylene glycol PEG and glycolide GA, wherein the number average molecular weight ratio of PLGA to PEG is (1.5-3):1, and the molar ratio of LA to GA is (3-5):1. For the in-vivo in-situ drug-loading hydrogel carrier provided by the invention, by embedding bone growth promoting factors, when natural marrow fills a porous artificial bone scaffold, the release of important signal factors during the fracture repairing process can be simulated, and thus the in-vivo in-situ drug-loading hydrogel carrier is well applied to the fields of improving spinal fusion, bone ununion, bone defect repair, and the like.

The present invention concerns polymer particles made from poly(lactic-co-glycolic acid) (PLGA) polymer, poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid) (PLGA-PEG-PLGA) copolymer, or the mixture of same, combined with hyaluronic acid molecules or hyaluronic acid salts, and the method for preparing same. The present invention also concerns injectable pharmaceutical or cosmetic compositions comprising such polymer particles, the method for preparing such compositions, and the use thereof for medical purposes, in particular for the prevention and/or treatment of musculoskeletal diseases, diseases and traumatic conditions of the skin, oral disorders, vaginal mucosa dryness and urinary infections or cystitis, dryness of the eye membrane and eye infections, obesity, and the use of same to combat ageing of the skin and/or for repairing the dermal tissue (mesotherapy). More particularly, the compositions of the invention can be intended to supplement joint fluids, and in particular synovial fluid, restoring the physiological and rheological conditions of pathological joints, for example arthritic joints, or indeed for treating and repairing the epidermis by remodelling, hydrating and protecting the skin.